background
commerci
multiplex
pcr
panel
respiratori
virus
prv
recent
develop
resplex
ii
panel
qiagen
multicod
plx
eragen
bioscienc
xtag
luminex
prv
studi
assay
detect
influenza
b
adenoviru
parainfluenza
respiratori
syncyti
viru
b
human
metapneumoviru
human
rhinoviru
resplex
ii
addit
detect
coronaviru
coxsackieecho
viru
bocaviru
differenti
adenovirus
b
e
multicodeplx
assay
detect
differenti
parainfluenza
adenovirus
b
c
e
xtag
addit
subtyp
influenza
season
studi
design
specimen
collect
adult
patient
sign
respiratori
infect
novemb
may
use
evalu
perform
three
commerci
prv
assay
viral
cultur
xtag
use
standard
assess
sensit
specif
result
prv
assay
detect
virus
cultur
compar
cultur
xtag
prv
show
sensit
specif
compar
multicodeplx
resplex
ii
respect
coinfect
detect
small
subset
patient
specimen
panel
show
differ
sensit
individu
virus
conclus
resplex
ii
multicodeplx
offer
broader
viru
detect
rang
greater
eas
use
xtag
prv
show
increas
sensit
common
viral
target
repres
assay
also
abil
differenti
human
nonhuman
influenza
respiratori
viral
infect
account
mani
hospit
death
us
addit
classic
respiratori
virus
newli
identifi
virus
human
metapneumoviru
hmpv
coronavirus
bocaviru
recent
influenza
viru
caus
signific
morbid
mortal
rapid
accur
diagnosi
respiratori
viral
pathogen
aid
antivir
therapi
earli
diagnosi
potenti
reduc
complic
antibiot
util
unnecessari
laboratori
test
develop
sensit
molecular
assay
increas
detect
rate
respiratori
viral
pathogen
pcr
nucleic
acid
sequenc
shown
greater
sensit
direct
fluoresc
antibodi
dfa
cultur
test
multiplex
pcr
assay
detect
multipl
respiratori
virus
xtag
one
first
multiplex
pcr
assay
clear
us
food
drug
administr
fda
detect
differ
respiratori
virus
nasopharyng
specimen
sinc
addit
commerci
panel
respiratori
virus
prv
assay
emerg
compar
studi
shown
xtag
consist
perform
better
nonmolecular
assay
comparison
xtag
publish
rel
multiplex
prv
assay
goal
studi
evalu
perform
fdaclear
xtag
research
use
resplex
ii
multicodeplx
detect
multipl
virus
subtyp
variou
clinic
specimen
type
compar
perform
viral
cultur
xtag
specimen
adult
patient
present
sign
symptom
respiratori
infect
novemb
may
includ
sampl
consist
bronchoalveolar
lavag
bal
nare
throat
nasopharyng
swab
lung
biopsi
pleural
fluid
sputa
flock
swab
specimen
submit
viral
transport
medium
vtm
bectondickinson
md
liquid
specimen
filter
dilut
vtm
prior
test
lung
biopsi
homogen
spun
supernat
dilut
vtm
ml
specimen
inocul
rmix
shell
vial
tissu
cultur
cell
primari
monkey
kidney
human
fibroblast
diagnost
hybrid
athen
oh
rmix
shell
vial
centrifug
rpm
h
inocul
cell
incub
c
rmix
shell
vial
stain
individu
monoclon
antibodi
influenza
flu
b
parainfluenza
para
adenoviru
respiratori
syncyti
viru
rsv
diagnost
hybrid
athen
adeno
oh
h
cultur
cell
observ
cytopath
chang
day
intern
control
prv
assay
ad
l
individu
specimen
prior
extract
extract
perform
use
qiagen
viru
minikit
nucleic
acid
elut
l
amplificationdetect
perform
per
manufactur
instruct
eragen
qiagen
luminex
detect
virus
prv
assay
base
xmap
technolog
use
luminex
instrument
prv
assay
differ
analysi
step
chemistri
detect
supplementari
tabl
multicodeplx
integr
multiplex
pcr
one
step
enzym
site
specif
enzymat
label
resplex
ii
util
suspens
array
use
qiagen
proprietari
one
step
qiaplex
pcr
superprim
qiagen
liquichip
system
xtag
employ
multipl
enzym
includ
luminex
suspens
microarray
platform
strict
adher
good
lab
techniqu
requir
follow
cutoff
valu
use
xtag
posit
mean
fluoresc
intens
mfi
base
manufactur
packag
insert
resplex
ii
multicodeplx
result
consid
posit
averag
signal
greater
standard
deviat
neg
control
signal
typic
mfi
resplex
ii
mfi
multicodeplx
respect
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
calcul
comparison
cultur
three
prv
assay
xtag
resplex
ii
multicodeplx
agreement
method
assess
kappa
valu
test
kappa
valu
indic
moder
almost
perfect
agreement
respect
one
hundr
twelv
specimen
n
neg
cultur
prv
specimen
highest
posit
rate
nare
supplementari
tabl
xtag
multicodeplx
posit
specimen
resplex
ii
singl
infect
flua
flub
rsvb
preval
gener
prv
assay
detect
higher
number
virus
compar
cultur
base
larger
repertoir
viral
target
detect
except
cultur
sensit
resplex
ii
multicodeplx
although
case
xtag
detect
n
compar
cultur
tabl
perform
prv
rel
cultur
compar
cultivat
virus
tabl
xtag
show
highest
sensit
npv
tabl
resplex
ii
show
highest
specif
ppv
kappa
variabl
show
highest
valu
xtag
follow
resplex
ii
multicodeplx
confirm
almost
perfect
agreement
xtag
compar
cultur
tabl
singl
virus
preval
detect
low
rate
multipl
viral
infect
depend
assay
multicodeplx
detect
dual
fluahmpv
rsvbhrv
tripl
infect
xtag
detect
dual
rsvbhrv
fluahmpv
resplex
ii
detect
dual
rsvbhrv
fluahmpv
cvevhrv
infect
multipl
infect
includ
parainfluenza
viru
interestingli
detect
part
multipl
infect
three
prv
assay
perform
similarli
detect
adeno
flub
rsvb
resplex
ii
multicodeplx
detect
similar
number
hmpv
n
n
respect
rsva
n
xtag
assay
detect
n
rsv
n
flua
n
compar
better
cultur
tabl
specimen
flua
posit
season
two
neither
later
confirm
data
shown
greatest
variabl
observ
detect
hrventeroviru
xtag
detect
greater
number
hrventeroviru
n
resplex
ii
detect
multicodeplx
detect
tabl
resplex
ii
differenti
hrv
cvev
four
specimen
posit
xtag
hrventeroviru
resplex
ii
detect
cvev
two
specimen
posit
hrv
multicodeplx
resplex
ii
detect
cvev
fda
approv
version
xtag
result
coronavirus
parainfluenza
target
screen
assay
includ
comparison
purpos
coronavirus
two
specimen
posit
resplex
ii
multicodeplx
prv
none
xtag
two
specimen
posit
resplex
ii
one
multicodeplx
xtag
respect
tabl
multicodeplx
panel
detect
resplex
ii
detect
adeno
c
adeno
e
latter
also
detect
multicodeplx
xtag
although
xtag
differenti
adeno
subtyp
resplex
ii
highest
number
intern
control
ic
failur
attribut
sampl
inhibit
sinc
amplif
ic
prv
assay
observ
sampl
neg
specimen
base
result
obtain
two
prv
multicodeplx
one
ic
failur
specimen
strongli
posit
xtag
ic
failur
six
specimen
posit
hrv
adeno
flub
rsva
one
specimen
neg
virus
posit
ic
upon
repeat
test
comparison
xtag
multicodeplx
show
highest
sensit
npv
howev
resplex
ii
specif
higher
ppv
kappa
resplex
ii
multicodeplx
respect
tabl
specimen
consid
discrep
cultur
prv
assay
result
correl
thirtysix
discrep
sampl
retest
use
previous
isol
nucleic
acid
store
c
upon
retest
specimen
correl
remain
specimen
flub
rsvb
posit
multicodeplx
xtag
neg
resplex
ii
addit
one
specimen
posit
resplex
ii
posit
xtag
neg
multicodeplx
data
shown
multicodeplx
higher
number
fals
neg
rsva
hrvcvev
flua
four
posit
hrv
multicodeplx
two
posit
xtag
hrventero
cvev
resplex
ii
xtag
panel
posit
hmpv
rsva
hrv
data
shown
nucleic
acid
amplif
test
shown
increas
sensit
faster
report
compar
nonamplif
test
higher
detect
rate
attribut
due
inclus
larg
number
viral
target
includ
newli
identifi
virus
cultur
andor
dfa
avail
also
due
increas
sensit
allow
detect
low
level
viru
latter
especi
import
older
adult
shed
low
titer
virus
compar
children
typic
shed
larger
titer
ultim
accur
diagnosi
optim
antivir
treatment
implement
infect
control
public
health
measur
new
commerci
system
avail
ensur
standard
qualiti
control
xtag
shown
better
perform
compar
dfa
howev
compar
data
newer
commerci
multiplex
prv
assay
lack
predict
prv
assay
sensit
viral
cultur
xtag
show
best
sensit
common
viral
target
compar
resplex
ii
multicodeplx
assay
previou
studi
shown
multicodeplx
highli
sensit
detect
flua
viral
target
studi
multicodeplx
detect
flua
flub
adeno
miss
cultur
howev
miss
flua
hrv
rsva
detect
prv
assay
tabl
addit
encount
specimen
posit
confirm
resplex
ii
xtag
cultur
data
shown
may
reflect
low
primer
specif
agent
resplex
ii
shown
good
correl
dfa
cross
reactiv
report
intern
control
failur
note
resplex
ii
previous
describ
minim
xtag
multicodeplx
assay
compar
cultur
sensit
multicodeplx
show
higher
specif
tabl
parainfluenza
cross
reactiv
observ
resplex
ii
detect
rsva
compar
xtag
resplex
ii
show
lower
sensit
multicodeplx
howev
depict
higher
specif
tabl
overal
xtag
show
highest
reproduc
sensit
specif
compar
valu
report
product
insert
specimen
studi
detect
adenoviru
parainfluenza
virus
howev
extens
evalu
adenoviru
serotyp
warrant
due
lack
detect
serotyp
per
product
insert
detect
low
rate
coinfect
compar
previou
studi
howev
rel
contribut
potenti
pathogen
clear
time
number
target
subtyp
differenti
vari
assay
xtag
detect
lower
number
viral
target
compar
resplex
ii
multicodeplx
differenti
adenovirus
enterovirus
hrv
interestingli
two
case
multicodeplx
report
hrv
resplex
ii
report
cvev
proprietari
natur
primer
probe
difficult
know
differenti
hrv
enterovirus
accomplish
reliabl
sequenc
perform
due
lack
remain
sampl
test
cultur
three
prv
assay
includ
discord
test
xtag
assay
distinguish
influenza
season
subtyp
influenza
outbreak
nonsubtyp
influenza
result
indic
novel
influenza
prove
use
save
valuabl
laboratori
resourc
time
reflex
second
confirmatori
assay
assay
perform
turn
around
time
eas
use
cost
regulatori
statu
import
factor
consid
choos
multiplex
pcr
assay
prv
assay
differ
analysi
step
chemistri
detect
supplementari
tabl
assay
complex
impact
turnaround
time
influenc
patient
manag
resplex
ii
gener
result
h
easi
perform
one
reagent
prepar
step
amplif
step
bead
hybrid
detect
report
result
second
step
perform
quick
success
hand
xtag
labor
intens
h
due
five
distinct
reagent
prepar
step
two
differ
thermocycl
program
complex
enzym
reagent
xtag
resplex
ii
requir
one
thermocycl
multicodeplx
requir
two
thermocycl
one
reversetranscriptas
targetspecificprimerextens
perform
separ
area
multicodeplx
postamplif
step
carri
room
temperatur
without
transfer
wash
complet
h
drawback
prv
assay
open
platform
potenti
prone
contamin
summari
perform
prv
assay
yield
better
sensit
compar
cultur
assay
show
differ
sensit
individu
virus
resplex
ii
test
offer
broadest
rang
viru
detect
multicodeplx
greatest
eas
use
xtag
show
increas
sensit
abil
subtyp
influenza
new
gener
assay
promis
enhanc
sensit
faster
turn
around
time
addit
viral
bacteri
target
multiplex
assay
assist
identifi
respiratori
viru
infect
aid
patient
manag
investig
outbreak
none
applic
